key: cord-0815211-6rs86u5v
authors: XIANG, JIANLIN; WEN, JING; YUAN, XIAOQING; Xiong, Shun; ZHOU, XUE; LIU, CHANGJIN; MIN, XUN
title: Potential biochemical markers to identify severe cases among COVID-19 patients
date: 2020-03-23
journal: nan
DOI: 10.1101/2020.03.19.20034447
sha: b7c708b318e96c87cf00ba5a46261d4c0c293376
doc_id: 815211
cord_uid: 6rs86u5v

There is a high mortality and long hospitalization period for severe cases with 2019 novel coronavirus disease (COVID-19) pneumonia. Therefore, it makes sense to search for a potential biomarker that could rapidly and effectively identify severe cases early. Clinical samples from 28 cases of COVID-19 (8 severe cases, 20 mild cases) in Zunyi District from January 29, 2020 to February 21, 2020 were collected and otherwise statistically analysed for biochemical markers. Serum urea, creatinine (CREA) and cystatin C (CysC) concentrations in severe COVID-19 patients were significantly higher than those in mild COVID-19 patients (P<0.001), and there were also significant differences in serum direct bilirubin (DBIL), cholinesterase (CHE) and lactate dehydrogenase (LDH) concentrations between severe and mild COVID-19 patients (P<0.05). Serum urea, CREA, CysC, DBIL, CHE and LDH could be used to distinguish severe COVID-19 cases from mild COVID-19 cases. In particular, serum biomarkers, including urea, CREA, CysC, which reflect glomerular filtration function, may have some significance as potential indicators for the early diagnosis of severe COVID-19 and to distinguish it from mild COVID-19. Glomerular filtration function injury in severe COVID-19 patients should also be considered by clinicians.

To date, the 2019 novel coronavirus pneumonia (COVID-19) is the greatest public health problem in the world. By 10:30 on Mar 19, 2020, the cumulative number of confirmed cases had reached 218,785 globally, including 8,949 deaths. Of the total confirmed COVID-19 patients, about 19.9% were severe cases [1] , which have a mortality rate of about 20%. Severe cases often suffer from underlying diseases such as cardiovascular disease and diabetes that can accelerate the progression of 2019 novel coronavirus (SARS-CoV-2) infection [2, 3] . Furthermore, acute respiratory distress syndrome could lead to death in some severe COVID-19 patients, and this is often accompanied by heart failure, liver failure, and kidney failure [2, 4] . Therefore, early, simple and effective diagnosis of severe COVID-19 pneumonia is of great significance in reducing mortality and shortening the hospitalization period.

2 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The guidelines on the diagnosis and treatment of novel coronavirus pneumonia [5] [6] [7] have clear criteria for severe COVID-19, including respiratory rate, haemoglobin oxygen saturation (SaO2), oxygenation index (PaO2/FiO2), and so on. However, these criteria are susceptible to subjective and objective factors, which may lead to an extended time for diagnosing and the possibility of misdiagnosing severe COVID-19. Therefore, it makes sense to find a potential biomarker that could effectively diagnose severe COVID-19.

In this study, we investigated and analysed more than 4,000 test results from 28 COVID-19

patients. The concentrations of 6 serum biochemical markers showed significant differences between severe and mild COVID-19 patients. Interestingly, the levels of serum biomarkers reflecting glomerular filtration function (including cystatin C (CysC), creatinine (CREA), and urea) in severe COVID-19 patients were significantly higher than those in mild patients. It has been demonstrated that serum urea, CREA and CysC could be potential biomarkers that could rapidly and specifically reflect severe COVID-19, and it is of great significance in the early diagnosis of COVID-19 to reduce the mortality and shorten the hospitalization period for patients with severe COVID-19. Moreover, glomerular filtration injury in patients with severe COVID-19 should not be ignored by clinicians.

The study enrolled patients who were diagnosed with COVID-19 at The First Affiliated Hospital of Zunyi Medical University and The Fourth People's Hospital of Zunyi city from January 29, 2020 to February 21, 2020. The exclusion criteria were based on the guidelines for the diagnosis and treatment of novel coronavirus pneumonia [6] . The inclusion criteria for participants are shown in Figure 1 .

3 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in software. The Wilcoxon signed-rank test was used to compare the data between two groups.

Differences with a value of P<0.05 were considered statistically significant.

In this study, the majority of serum biochemical markers, including UA, HCO 3 perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Glomerular filtration function markers, such as serum urea, CREA and CysC, were significantly higher in severe COVID-19 patients than in mild COVID-19 patients (P<0.001) ( Figure 3A , B, C). There were also significant differences in serum DBIL, CHE and LDH 6 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 23, 2020. . https://doi.org/10.1101/2020.03.19.20034447 doi: medRxiv preprint concentrations between severe and mild COVID-19 patients (P<0.05) ( Figure 3D , E, F). 

In this paper, the results of most serum biochemical tests were investigated and analysed. The incidence of liver or heart failure was higher in severe COVID-19 patients [2, 4] ; however, we found that most of the indicators, including liver and cardiac function biomarkers, except for serum DBIL, CHE and LDH, did not change significantly or directly in severe and mild patients. There were not much consistent with some reports in the literature [2] , which may be the result of prophylactic use of drug by doctors. There were also no differences in serum CRP concentrations between severe and mild COVID-19 patients; however, the overall level of serum CRP increased, suggesting that it could be sensitive to SARS-CoV-2 infection.

The results of renal injury were similar with 2003 SARS-CoV [8] , a close relative of 7 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted March 23, 2020. . https://doi.org/10.1101/2020.03.19.20034447 doi: medRxiv preprint SARS-CoV-2. We also found that serum urea, CREA, and CysC, which are biochemical markers of renal function, were significantly elevated in severe COVID-19 patients, suggesting that SARS-CoV-2 infection could damage the kidney, and this is consistent with part of the latest findings [9] . Furthermore, there were no differences in the serum HCO 3- results between severe and mild COVID-19 patients, and this further suggests that the glomerulus could be one of the target organs for the coronavirus in severe patients and may be related to the high expression of ACE2 in glomerular cells [10, 11] .

Two limitations are inherent in our study. First, the survey area is relatively limited.

Additionally, the relatively small number of participants in the survey may not fully reflect the overall situation. Thus, further studies are necessary to execute a large number of data surveys in multiple regions by multi-centre cooperation.

Herein, we found that some serum indicators of glomerular function, including urea, CREA, and CysC, were observably higher in severe COVID-19 patients than in mild COVID-19

patients. This result indicates that serum urea, CREA, and CysC could be used as potential biochemical biomarkers to identify a severe COVID-19 patient. Moreover, clinicians should constantly monitor the glomerular filtration function while treating patients with a severe SARS-CoV-2 infection.

Report of the CHINA-WHO joint investigation on new coronavirus pneumonia (COVID -19)

Clinical features of patients infected with 2019 novel coronavirus in

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

The notice of launching guideline on diagnosis and treatment of the novel coronavirus pneumonia (NCP)

The notice of launching guideline on diagnosis and treatment of the novel coronavirus pneumonia (NCP)

The notice of launching guideline on diagnosis and treatment of the novel coronavirus pneumonia (NCP)

Acute renal impairment in coronavirus-associated severe acute respiratory syndrome

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted

Caution on Kidney Dysfunctions of 2019-nCoV Patients, medRxiv

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

The authors wish to thank all the patients who enrolled in this study.

This study was supported by the Science and Technology Program of Zunyi (grant numbers

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in